IBD
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence.
Clinical takeawayNo change to individual patient management. For clinicians in East and Southeast Asia, this reinforces that IBD burden will continue rising with progression through stage 3 (compounding prevalence), informing healthcare system planning and resource allocation. For clinicians elsewhere, this contextualizes the global rise in IBD associated with economic development.
What it foundIBD incidence in East and Southeast Asia (Japan, South Korea, China, Hong Kong, Malaysia) is accelerating through stage 2 of a four-stage epidemiological progression: stage 1 (emergence), stage 2 (acceleration in incidence), stage 3 (compounding prevalence), and stage 4 (prevalence equilibrium). Each region currently sits in the early, middle, or late phase of stage 2, following the same trajectory that early-industrialised Western regions (Europe, North America, Oceania) have followed; most Western regions have now reached stage 3.
ContextConfirms the established four-stage model of IBD's epidemiological progression following industrialisation. Extends this known Western trajectory to Asia, showing the region follows the same pattern rather than diverging. Opens questions about interventions during the acceleration phase (stage 2) that might alter the disease's trajectory in other emerging economies.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Okabayashi S … Kaplan GG · Lancet Gastroenterology & Hepatology · IF 39.1 · PubMed ↗